Triamcinolone Hexacetonide 20 MG/ML ( DrugBank: Triamcinolone )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 107 | Juvenile idiopathic arthritis | 1 |
107. Juvenile idiopathic arthritis
Clinical trials : 447 / Drugs : 297 - (DrugBank : 57) / Drug target genes : 52 - Drug target pathways : 146
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04614311 (ClinicalTrials.gov) | December 1, 2020 | 28/10/2020 | Strategies Towards Personalised Treatment in Juvenile Idiopathic Arthritis (JIA). | Strategies Towards Personalised Treatment in Juvenile Idiopathic Arthritis (JIA): The MyJIA Trial. | Juvenile Idiopathic Arthritis | Drug: Triamcinolone Hexacetonide 20 MG/ML | Oslo University Hospital | The Research Council of Norway;Haukeland University Hospital;St. Olavs Hospital;University Hospital of North Norway;Helse Stavanger HF | Recruiting | 1 Year | 18 Years | All | 202 | Phase 4 | Norway |